2.1
Efgartigimod (Vyvgart, Argenx) is indicated as 'an add-on to standard therapy for the treatment of adult patients with generalised Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive'.
2 Information about efgartigimod
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedules are available in the summary of product characteristics for efgartigimod (concentrate for solution for infusion and solution for injection).
Price
2.3
The list price of efgartigimod is £6,569.73 per 400‑mg solution for infusion vial and £15,307.47 per 1,000‑mg solution for injection vial (excluding VAT, company submission).
2.4
The company has a commercial arrangement, which would have applied if efgartigimod had been recommended.